RT Journal Article
SR Electronic
T1 Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.03.22280351
DO 10.1101/2022.10.03.22280351
A1 Wu, Eveline Y.
A1 Oliver, Melissa
A1 Scheck, Joshua
A1 Lapidus, Sivia
A1 Akca, Ummusen Kaya
A1 Yasin, Shima
A1 Stern, Sara M.
A1 Insalaco, Antonella
A1 Pardeo, Manuela
A1 Simonini, Gabriele
A1 Marrani, Edoardo
A1 Wang, Xing
A1 Huang, Bin
A1 Kovalick, Leonard K.
A1 Rosenwasser, Natalie
A1 Casselman, Gabriel
A1 Liau, Adriel
A1 Shao, Yurong
A1 Yang, Claire
A1 Mosa, Doaa Mosad
A1 Tucker, Lori
A1 Girschick, Hermann
A1 Laxer, Ronald M.
A1 Akikusa, Jonathan D.
A1 Hedrich, Christian
A1 Onel, Karen
A1 Dedeoglu, Fatma
A1 Twilt, Marinka
A1 Ferguson, Polly J.
A1 Ozen, Seza
A1 Zhao, Yongdong
YR 2023
UL http://medrxiv.org/content/early/2023/02/13/2022.10.03.22280351.abstract
AB Introduction Prospective comparative effectiveness research in chronic nonbacterial osteomyelitis (CNO) is lacking.Objectives Study objectives were to: 1) determine the use and safety of each consensus treatment plan (CTP) regimen for CNO, 2) the feasibility of using chronic nonbacterial osteomyelitis international registry (CHOIR) data for comparative effectiveness research, and 3) develop and validate a CNO clinical disease activity score (CDAS) using CHOIR.Methods Consenting children or young adults with CNO were enrolled into CHOIR. Demographic, clinical, and imaging data were prospectively collected. The CNO CDAS was developed through a Delphi survey and nominal group technique. External validation surveys were administered to CHOIR participants.Results 140 (76%) CHOIR participants enrolled between August 2018 and September 2020 received at least one CTP regimen. Baseline characteristics from the three groups were well matched. Patient pain, patient global assessment, and clinical CNO lesion count were key variables included in the CNO CDAS. The CDAS showed a strong correlation with patient/parent report of difficulty using a limb, back, or jaw and patient/parent report of disease severity, but a weak correlation with patient/parent report of fatigue, sadness, and worry. The change in CDAS was significant in patients reporting disease worsening or improvement. The CDAS significantly decreased after initiating second-line treatments from median 12 (8-15.5) to 5 (3-12). While second-line treatments were well tolerated, psoriasis was the most common adverse event.Conclusion The CNO CDAS was developed and validated for disease monitoring and assessment of treatment effectiveness. CHOIR provided a comprehensive framework for future comparative effectiveness research.Key messagesThe chronic nonbacterial osteomyelitis international registry (CHOIR) provides comprehensive prospective data for comparison of treatment effectivenessThe clinical disease activity score (CDAS) has content and construct validity to assess CNOCompeting Interest StatementDr. Wu receives advisory board fees from Pharming Healthcare, Inc. and research funding from Bristol-Myers Squibb, Janssen, and Enzyvant. Dr. Oliver served as a committee member on ACR RheumPAC. Dr. Stern received a Sjogren Foundation Grant and served in the Arthritis Foundation Medical Advisory for Idaho and Utah. Dr. Tucker served as a Board member of the Cassie & Friends Society. Dr. Ozen received consulting fees from Novartis and SOBI. Dr. Zhao received research funding from Bristol-Myers Squibb, royalties from UptoDate and consulting fees from Novartis in 2020. Dr. Ferguson is supported by the Marjorie K. Lamb Professorship, serves on the American Board of Pediatrics Pediatric Rheumatology Subboard, has funding from the NIH (NINDS and NICHD) and received a consulting fee from Novartis in 2020. Dr. Dedeoglu receives royalties from UptoDate and received a consulting fee from Novartis in 2020. Dr. Twilt serves on the TMJaw board and has received funding support from CARRA, the Arthritis Society, and CIHR. Dr. Laxer receives royalties from UptoDate, consulting fees from Sobi, Novartis, Eli Lilly, Sanofi, Sobi, serves on the Education Committee of the ACR, and on the Board of the CRMO Foundation, CACP Foundation and Canadian Autoinflammatory Network. Dr. Akikusa received honoraria from Novartis in 2022.Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04725422 Funding StatementThe CRMO Warriors Guild of the Seattle Childrens Foundation supported the data collection at Seattle Childrens Hospital, coordination of all participating sites, and the statistical analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Seattle Childrens' Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors